Engineered Aptamer-Organic Amphiphile Self-Assemblies for Biomedical Applications: Progress and Challenges
- PMID: 34622570
- DOI: 10.1002/smll.202104341
Engineered Aptamer-Organic Amphiphile Self-Assemblies for Biomedical Applications: Progress and Challenges
Abstract
Currently, nucleic acid aptamers are exploited as robust targeting ligands in the biomedical field, due to their specific molecular recognition, little immunogenicity, low cost, ect. Thanks to the facile chemical modification and high hydrophilicity, aptamers can be site-specifically linked with hydrophobic moieties to prepare aptamer-organic amphiphiles (AOAs), which spontaneously assemble into aptamer-organic amphiphile self-assemblies (AOASs). These polyvalent self-assemblies feature with enhanced target-binding ability, increased resistance to nuclease, and efficient cargo-loading, making them powerful platforms for bioapplications, including targeted drug delivery, cell-based cancer therapy, biosensing, and bioimaging. Besides, the morphology of AOASs can be elaborately manipulated for smarter biomedical functions, by regulating the hydrophilicity/hydrophobicity ratio of AOAs. Benefiting from the boom in DNA synthesis technology and nanotechnology, various types of AOASs, including aptamer-polymer amphiphile self-assemblies, aptamer-lipid amphiphile self-assemblies, aptamer-cell self-assemblies, ect, have been constructed with great biomedical potential. Particularly, stimuli-responsive AOASs with transformable structure can realize site-specific drug release, enhanced tumor penetration, and specific target molecule detection. Herein, the general synthesis methods of oligonucleotide-organic amphiphiles are firstly summarized. Then recent progress in different types of AOASs for bioapplications and strategies for morphology control are systematically reviewed. The present challenges and future perspectives of this field are also discussed.
Keywords: amphiphile self-assembly; aptamers; biomedical application; morphology control; synthesis.
© 2021 Wiley-VCH GmbH.
Similar articles
-
Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics.Chem Soc Rev. 2024 Jul 1;53(13):6830-6859. doi: 10.1039/d3cs00774j. Chem Soc Rev. 2024. PMID: 38829187 Review.
-
Effect of polyethylene glycol, alkyl, and oligonucleotide spacers on the binding, secondary structure, and self-assembly of fractalkine binding FKN-S2 aptamer-amphiphiles.Langmuir. 2014 Jul 1;30(25):7465-74. doi: 10.1021/la500403v. Epub 2014 Jun 17. Langmuir. 2014. PMID: 24849928
-
Aptamer-functionalized nucleic acid nanotechnology for biosensing, bioimaging and cancer therapy.Nanoscale. 2025 Jan 2;17(2):687-704. doi: 10.1039/d4nr04360j. Nanoscale. 2025. PMID: 39585179 Review.
-
Molecular Engineering of Aptamer Self-Assemblies Increases in Vivo Stability and Targeted Recognition.ACS Nano. 2022 Jan 25;16(1):169-179. doi: 10.1021/acsnano.1c05265. Epub 2021 Dec 22. ACS Nano. 2022. PMID: 34935348
-
Recent progresses in biomedical applications of aptamer-functionalized systems.Bioorg Med Chem Lett. 2017 Sep 15;27(18):4256-4269. doi: 10.1016/j.bmcl.2017.03.032. Epub 2017 Mar 18. Bioorg Med Chem Lett. 2017. PMID: 28803753 Review.
Cited by
-
Recent Advances in CRISPR/Cas-Based Biosensors for Protein Detection.Bioengineering (Basel). 2022 Sep 28;9(10):512. doi: 10.3390/bioengineering9100512. Bioengineering (Basel). 2022. PMID: 36290480 Free PMC article. Review.
-
Advancements in SELEX Technology for Aptamers and Emerging Applications in Therapeutics and Drug Delivery.Biomolecules. 2025 Jun 5;15(6):818. doi: 10.3390/biom15060818. Biomolecules. 2025. PMID: 40563458 Free PMC article. Review.
-
Hyperbranched Polymers: Recent Advances in Photodynamic Therapy against Cancer.Pharmaceutics. 2023 Aug 28;15(9):2222. doi: 10.3390/pharmaceutics15092222. Pharmaceutics. 2023. PMID: 37765191 Free PMC article. Review.
-
Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.J Exp Clin Cancer Res. 2024 Jul 25;43(1):207. doi: 10.1186/s13046-024-03133-5. J Exp Clin Cancer Res. 2024. PMID: 39054545 Free PMC article.
-
Iron Oxide Nanoparticle-Based T1 Contrast Agents for Magnetic Resonance Imaging: A Review.Nanomaterials (Basel). 2024 Dec 28;15(1):33. doi: 10.3390/nano15010033. Nanomaterials (Basel). 2024. PMID: 39791792 Free PMC article. Review.
References
-
- a) H. Xiong, J. Yan, S. Cai, Q. He, D. Peng, Z. Liu, Y. Liu, Int. J. Biol. Macromol. 2019, 132, 190;
-
- b) J. Yan, H. Xiong, S. Cai, N. Wen, Q. He, Y. Liu, D. Peng, Z. Liu, Talanta 2019, 200, 124.
-
- a) G. Zhu, G. Niu, X. Chen, Bioconjugate Chem. 2015, 26, 2186;
-
- b) L. Zhang, S. Wan, Y. Jiang, Y. Wang, T. Fu, Q. Liu, Z. Cao, L. Qiu, W. Tan, J. Am. Chem. Soc. 2017, 139, 2532.
-
- a) F. Ding, Y. Gao, X. He, Bioorg. Med. Chem. Lett. 2017, 27, 4256;
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical